IRF7 as an Immune-Related Prognostic Biomarker and Associated with Tumor Microenvironment in Low-Grade Glioma

References

• Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro-Oncology. 2018;20(suppl_4):iv1–iv86. doi:10.1093/neuonc/noy131
   PubMed Web of Science ®Google Scholar
• Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481–2498.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-1
   PubMed Web of Science ®Google Scholar
• Ceccarelli M, Barthel FP, Malta TM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550–563. doi:10.1016/j.cell.2015.12.028
   PubMed Web of Science ®Google Scholar
• Xu S, Tang L, Li X, Fan F, Liu Z. Immunotherapy for glioma: current management and future application. Cancer Lett. 2020;476:1–12. doi:10.1016/j.canlet.2020.02.002
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12(6):583–593. doi:10.1016/S1470-2045(11)70057-2
   PubMed Web of Science ®Google Scholar
• Hottinger AF, Hegi ME, Baumert BG. Current management of low-grade gliomas. Curr Opin Neurol. 2016;29(6):782–788. doi:10.1097/WCO.0000000000000390
   PubMed Web of Science ®Google Scholar
• Kim J, Bae JS. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediators Inflamm. 2016;2016:6058147. doi:10.1155/2016/6058147
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–1022. doi:10.1038/ni.2703
   PubMed Web of Science ®Google Scholar
• Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015;5(9):915–919. doi:10.1158/2159-8290.CD-15-0563
   PubMed Web of Science ®Google Scholar
• Pottier C, Wheatherspoon A, Roncarati P, et al. The importance of the tumor microenvironment in the therapeutic management of cancer. Expert Rev Anticancer Ther. 2015;15(8):943–954. doi:10.1586/14737140.2015.1059279
   PubMed Web of Science ®Google Scholar
• Watnick RS. The role of the tumor microenvironment in regulating angiogenesis. Cold Spring Harb Perspect Med. 2012;2(12):a006676. doi:10.1101/cshperspect.a006676
   PubMed Web of Science ®Google Scholar
• Angell H, Galon J. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013;25(2):261–267. doi:10.1016/j.coi.2013.03.004
   PubMed Web of Science ®Google Scholar
• Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;18(5):349–355. doi:10.1016/j.semcancer.2008.03.004
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–555. doi:10.1016/S1471-4906(02)02302-5
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677–686. doi:10.1016/j.it.2004.09.015
   PubMed Web of Science ®Google Scholar
• Zhou J, Nefedova Y, Lei A, Gabrilovich D. Neutrophils and PMN-MDSC: their biological role and interaction with stromal cells. Semin Immunol. 2018;35:19–28. doi:10.1016/j.smim.2017.12.004
   PubMed Web of Science ®Google Scholar
• Zhang S, Ke X, Zeng S, et al. Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment. Cell Mol Immunol. 2015;12(5):580–591. doi:10.1038/cmi.2015.57
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zha Y, Spaapen RM, et al. Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy. Mol Immunol. 2013;55(3–4):283–291. doi:10.1016/j.molimm.2013.03.006
   PubMed Web of Science ®Google Scholar
• Gros A, Robbins PF, Yao X, et al. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246–2259. doi:10.1172/JCI73639
   PubMed Web of Science ®Google Scholar
• Zhang L, Pagano JS. Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1. J Virol. 2000;74(3):1061–1068. doi:10.1128/JVI.74.3.1061-1068.2000
   PubMed Web of Science ®Google Scholar
• Ning S, Hahn AM, Huye LE, Pagano JS. Interferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1: a regulatory circuit. J Virol. 2003;77(17):9359–9368. doi:10.1128/JVI.77.17.9359-9368.2003
   PubMed Web of Science ®Google Scholar
• Ning S, Pagano JS, Barber GN. IRF7: activation, regulation, modification and function. Genes Immun. 2011;12(6):399–414. doi:10.1038/gene.2011.21
   PubMed Web of Science ®Google Scholar
• Sprooten J, Garg AD. Type I interferons and endoplasmic reticulum stress in health and disease. Int Rev Cell Mol Biol. 2020;350:63–118.
   PubMed Web of Science ®Google Scholar
• Barton GM, Kagan JC. A cell biological view of toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol. 2009;9(8):535–542. doi:10.1038/nri2587
   PubMed Web of Science ®Google Scholar
• Solis M, Goubau D, Romieu-Mourez R, Genin P, Civas A, Hiscott J. Distinct functions of IRF-3 and IRF-7 in IFN-alpha gene regulation and control of anti-tumor activity in primary macrophages. Biochem Pharmacol. 2006;72(11):1469–1476. doi:10.1016/j.bcp.2006.06.002
   PubMed Web of Science ®Google Scholar
• Jin X, Kim SH, Jeon HM, et al. Interferon regulatory factor 7 regulates glioma stem cells via interleukin-6 and Notch signalling. Brain. 2012;135(Pt 4):1055–1069. doi:10.1093/brain/aws028
   PubMed Web of Science ®Google Scholar
• Deng Y, Guo SL, Li JQ, et al. Interferon regulatory factor 7 inhibits rat vascular smooth muscle cell proliferation and inflammation in monocrotaline-induced pulmonary hypertension. Life Sci. 2021;264:118709. doi:10.1016/j.lfs.2020.118709
   PubMed Web of Science ®Google Scholar
• Lu R, Moore PA, Pitha PM. Stimulation of IRF-7 gene expression by tumor necrosis factor alpha: requirement for NFkappa B transcription factor and gene accessibility. J Biol Chem. 2002;277(19):16592–16598. doi:10.1074/jbc.M111440200
   PubMed Web of Science ®Google Scholar
• Makovski V, Jacob-Hirsch J, Gefen-Dor C, et al. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway. Cell Death Dis. 2014;5(12):e1557. doi:10.1038/cddis.2014.502
   PubMed Web of Science ®Google Scholar
• Bidwell BN, Slaney CY, Withana NP, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012;18(8):1224–1231. doi:10.1038/nm.2830
   PubMed Web of Science ®Google Scholar